In vitro assessment of the agonist properties of the novel 5-HT1A receptor ligand, CUMI-101 (MMP), in rat brain tissue

Nuclear Medicine and Biology

Volumn 38, Issue 2, 2011, Pages 273-277

  Hendry, Nicola ^a   Christie, Isabel ^a   Rabiner, Eugenii Alfredovich ^b   Laruelle, Marc ^a   Watson, Jeannette ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

5 HT1A; Cortex; CUMI 101; Hippocampus; MMP; WAY100635

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; CARBON 11; CUMI 101; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; O METHYL 2 [4 [4 (2 METHOXYPHENYL)PIPERAZIN 1 YL]BUTYL] 4 METHYL 1,2,4 TRIAZINE 3,5 (2H,4H)DIONE; SEROTONIN 1A AGONIST; SEROTONIN 1A RECEPTOR; SEROTONIN AGONIST; SULFUR 35; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN TISSUE; CELL STRAIN HEK293; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; EMBRYO; GENETIC TRANSFECTION; HIPPOCAMPUS; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; NONHUMAN; RADIOCHEMISTRY; RAT;

ANIMALS; BRAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HEK293 CELLS; HUMANS; LIGANDS; MALE; PIPERAZINES; POSITRON-EMISSION TOMOGRAPHY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN 5-HT1 RECEPTOR AGONISTS; SEROTONIN 5-HT1 RECEPTOR ANTAGONISTS; TRIAZINES;

EID: 79551684778     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2010.08.003     Document Type: Article

References (21)

1. Borg J. Molecular imaging of the 5-HT1A receptor in relation to human cognition. Behav Brain Res 2008, 195:103-111.
2. Salmon E. A review of the literature on neuroimaging of serotoninergic function in Alzheimer's disease and related disorders. J Neural Transm 2007, 114:1179-1185.
3. Savitz J., Lucki I., Drevets W.C. 5-HT1A receptor function in major depressive disorder. Prog Neurobiol 2009, 88:17-31.
4. Burnet P.W.I., Mefford I.N., Smith M.A., Gold P.W., Sternberg E.M. Hippocampal 5-HT1A receptor binding site densities, 5-HT1A receptor messenger ribonucleic acid abundance and serotonin levels parallel the activity of the hypothalamo-pituitary-adrenal axis in rats. Behav Brain Res 1995, 73:365-368.
5. Lanoir J., Hilaire G., Seif I. Reduced density of functional 5-HT1A receptors in the brain, medulla and spinal cord of monoamine oxidase-A knockout mouse neonates. J Comp Neurol 2006, 495:607-623.
6. Raymond J.R., Mukhin Y.V., Gettys T.W., Garnovskaya M.N. The recombinant 5-HT1A receptor: G protein coupling and signalling pathways. Br J Pharmacol 1999, 127:1751-1764.
7. Granas C., Nordquist J., Mohell N., Larhammar D. Site-directed mutagenesis of the 5-HT1B receptor increases the affinity of 5-HT for the agonist low-affinity conformation and reduces the intrinsic activity of 5-HT. Eur J Pharmacol 2001, 421:69-76.
8. Assiθ M.B., Koek W. Effects of 5-HT1A receptor antagonists on hippocampal 5-hydroxytryptamine levels: (S)-WAY100135, but not WAY100635, has partial agonist properties. Eur J Pharmacol 1996, 304:15-21.
9. Gozlan H., Thibault S., Laporte A.M., Lima L., Hamon M. The selective 5-HT1A antagonist radioligand [3H]WAY 100635 labels both G-protein-coupled and free 5-HT1A receptors in rat brain membranes. Eur J Pharmacol 1995, 288:173-186.
10. Laruelle M. Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb Blood Flow Metab 2000, 20:423-451.
11. Hume S., Hirani E., Opacka-Juffry J., Myers R., Townsend C., Pike V., et al. Effect of 5-HT on binding of [(11)C] WAY 100635 to 5-HT(IA) receptors in rat brain, assessed using in vivo microdialysis nd PET after fenfluramine. Synapse 2001, 41:150-159.
12. Kumar J.S.D., et al. Synthesis and in vivo evaluation of a novel 5-HT1A receptor agonist radioligand [O-methyl- 11C]2-(4-(4-(2-methoxyphenyl)piperazin-1-yl)butyl)-4-methyl-1,2,4-triazine -3,5(2H,4H)dione in nonhuman primates. Eur J Nucl Med Mol Imaging 2007, 34:1050-1060.
13. Kumar J.S.D., et al. Synthesis and in vivo validation of [O-methyl-11C]2-{4-[4-(7- methoxynaphthalen-1-yl)piperazin-1-yl]butyl}-4-methyl-2H-[1,2,4]triazine-3, 5-dione: a novel 5-HT1A receptor agonist positron emission tomography ligand. J Med Chem 2006, 49:125-134.
14. Albert P.R., Zhou Q.Y., Van Tol H.H., Bunzow J.R., Civelli O. Cloning, functional expression, and mRNA tissue distribution of the rat 5-hydroxytryptamine1A receptor gene. J Biol Chem 1990, 265:5825-5832.
15. Sharif N.A., Drace C.D., Williams G.W., Crider J.Y. Cloned human 5-HT1A receptor pharmacology determined using agonist binding and measurement of cAMP accumulation. J Pharm Pharmacol 2004, 56:1267-1274.
16. Watson J., et al. Functional effects of the muscarinic receptor agonist, xanomeline, at 5-HT1 and 5-HT2 receptors. Br J Pharmacol 1998, 125:1413-1420.
17. Cheng Y., Prusoff W.H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 1973, 22:3099-3108.
18. Khawaja X., Evans N., Reilly V., Ennis C., Minchin M.C. Characterisation of the binding of [3H]WAY-100635, a novel 5-hydroxytryptamine1A receptor antagonist, to rat brain. J Neurochem 1995, 64:2716-2726.
19. Varnas K., Halldin C., Hall H. Autoradiographic distribution of serotonin transporters and receptor subtypes in human brain. Hum Brain Mapp 2004, 22:246-260.
20. Caliendo G., Santagada V., Perissutti E., Fiorino F. Derivatives as 5HT1A receptor ligands - past and present. Curr Med Chem 2005, 12:1721-1753.
21. Nelson C.P., Challiss R.A. "Phenotypic" pharmacology: the influence of cellular environment on G protein-coupled receptor antagonist and inverse agonist pharmacology. Biochem Pharmacol 2007, 73:737-751.